Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 8, 2021updated 07 Jan 2022 6:43am

InDex enrols first subject in trial of cobitolimod for ulcerative colitis

The trial will enrol six subjects to assess the systemic uptake of the drug to treat colonic inflammation.

InDex Pharmaceuticals has enrolled the first subject in the clinical pharmacokinetic (PK) trial of its drug candidate, cobitolimod, to locally treat colonic inflammation in individuals with ulcerative colitis (UC).

A Toll-like receptor 9 (TLR9) agonist, cobitolimod can potentially offer a local anti‐inflammatory effect in the large intestine, which could stimulate mucosal healing and relieve the clinical symptoms of UC.

The trial will assess the systemic uptake of the drug to treat colonic inflammation enrolling a minimum of six subjects with moderate to severe UC.

These patients will receive 500mg doses of cobitolimod given rectally.

The uptake of the drug will initially be measured in active UC individuals and subsequently in those who respond to the therapy.

The study is carried out parallelly with the international Phase III CONCLUDE trial of cobitolimod that will recruit nearly 440 subjects in more than 30 countries.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The randomised, placebo-controlled, double-blind CONCLUDE trial will assess the drug as a new therapy to treat people with moderate to severe left-sided UC.

Last month, InDex had enrolled the first subject in the trial.

In the Phase IIb CONDUCT trial, cobitolimod met the primary goal and showed robust efficacy and safety.

Furthermore, the results from four prior placebo-controlled trials support the efficacy and safety found in the CONDUCT trial.

InDex Pharmaceuticals CEO Peter Zerhouni said: “With the PK study, we aim to confirm the limited systemic uptake of cobitolimod shown in previous preclinical and clinical studies.

“This likely contributes to cobitolimod’s excellent safety profile and is a significant advantage compared to the current systemically administered drugs for ulcerative colitis that can cause severe off-target effects.”

UC is a chronic disease that causes large intestine inflammation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy